National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure.
暂无分享,去创建一个
L. Newby | C. Cannon | D. Morrow | A. Wu | F. Apple | R. Christenson | A. Storrow | W. Tang | J. Ravkilde | G. Francis | R. Jesse | A. Wu | G. Francis | F. Apple | W. Tang
[1] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[2] Peter C Austin,et al. Relation between cardiac troponin I and mortality in acute decompensated heart failure. , 2007, American heart journal.
[3] Faquan Liang,et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.
[4] A. Akdoğan,et al. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? , 2007, Clinical Rheumatology.
[5] K. Furie,et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.
[6] J. Struck,et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. , 2007, Journal of cardiac failure.
[7] G. Brabant,et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.
[8] D. Phelan,et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. , 2007, Journal of cardiac failure.
[9] M. Padeletti,et al. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. , 2007, Journal of the American College of Cardiology.
[10] K. Bibbins-Domingo,et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.
[11] P. Donnan,et al. A critical re‐appraisal of different ways of selecting ambulatory patients with suspected heart failure for echocardiography , 2007, European journal of heart failure.
[12] P. Hildebrandt,et al. Unexplained week‐to‐week variation in BNP and NT‐proBNP is low in chronic heart failure patients during steady state , 2007, European journal of heart failure.
[13] Jacques Pouchot,et al. A gray zone assigned to inconclusive results of quantitative diagnostic tests: Application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. , 2006, Clinical chemistry.
[14] E. Perna,et al. Increased levels of cardiac troponin-T in outpatients with heart failure and preserved systolic function are related to adverse clinical findings and outcome , 2006, Coronary artery disease.
[15] S. Gottlieb,et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. , 2006, American heart journal.
[16] P. Richardson,et al. Interactions of two monoclonal antibodies with BNP: high resolution epitope mapping using fluorescence correlation spectroscopy. , 2006, Biochemistry.
[17] Takeshi Kimura,et al. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies , 2006, Heart and Vessels.
[18] Alan H B Wu,et al. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.
[19] J. Struck,et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.
[20] A. Dwyer,et al. Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department. , 2006, American heart journal.
[21] Y. Pinto,et al. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? , 2006, Journal of the American College of Cardiology.
[22] L. Tarantini,et al. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. , 2006, Journal of cardiac failure.
[23] S. Hazen,et al. Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.
[24] Y. Pinto,et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. , 2006, The American journal of cardiology.
[25] C. Forleo,et al. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy , 2006, European journal of heart failure.
[26] C. Frampton,et al. NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.
[27] S. Yusuf,et al. Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.
[28] B. Pathik,et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.
[29] M. Jessup,et al. Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction , 2006, Circulation.
[30] C. Schindler,et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.
[31] R. Rodeheffer,et al. Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure , 2006, Hypertension.
[32] A. Hoes,et al. Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge. , 2006, American heart journal.
[33] J. Hollander,et al. Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. , 2006, American heart journal.
[34] M. Pfisterer,et al. Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.
[35] C. Vergnes,et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. , 2006, American heart journal.
[36] C. Frampton,et al. Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.
[37] C. Camargo,et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.
[38] Antoni Bayes-Genis,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.
[39] R. Rodeheffer,et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.
[40] D. Lloyd‐Jones,et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.
[41] R. Doughty,et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. , 2006, Journal of the American College of Cardiology.
[42] R. Califf,et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.
[43] G. Fonarow,et al. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. , 2005, American heart journal.
[44] F. Fouad-Tarazi,et al. Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. , 2005, American heart journal.
[45] R. Califf,et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.
[46] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[47] M. Fraser,et al. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. , 2005, Congestive heart failure.
[48] D. Leosco,et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. , 2005, European heart journal.
[49] D. Arab,et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[50] S. Kong,et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. , 2005, Journal of cardiac failure.
[51] M. Chung,et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies , 2005, Heart.
[52] R. Woitas,et al. N-terminal pro-B-type natriuretic peptide and mortality in coronary heart disease. , 2005, The New England journal of medicine.
[53] C. Camargo,et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.
[54] D. Lloyd‐Jones,et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. , 2005, American heart journal.
[55] Eduardo R Perna,et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. , 2005, International journal of cardiology.
[56] L. Køber,et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.
[57] L. Wallentin,et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.
[58] R. Starling,et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. , 2005, American heart journal.
[59] M. Drazner,et al. Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. , 2005, American heart journal.
[60] Yigal M. Pinto,et al. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.
[61] A. Barbagelata,et al. Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification , 2004, Circulation.
[62] M. Quiñones,et al. Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters , 2004, Circulation.
[63] I. Squire,et al. Plasma urocortin in human systolic heart failure. , 2004, Clinical science.
[64] P. Hildebrandt,et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population , 2004, Heart.
[65] Daniel Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.
[66] M. Pfisterer,et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.
[67] D. Levy,et al. Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.
[68] James D. Thomas,et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.
[69] A. Richards,et al. The natriuretic peptides in heart failure , 2004, Basic Research in Cardiology.
[70] P. Hildebrandt,et al. N‐terminal‐pro‐B‐type natriuretic peptide (NT‐pro‐BNP) in different thyroid function states , 2004, Clinical endocrinology.
[71] F. van Lente,et al. Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.
[72] M. Packer. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? , 2003, Circulation.
[73] A. Wu,et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[74] Motoyuki Nakamura,et al. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. , 2003, American journal of hypertension.
[75] R. Doughty,et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. , 2003, Journal of the American College of Cardiology.
[76] Stephen J. Huang,et al. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients* , 2003, Critical care medicine.
[77] A. Maisel. The Diagnosis of Acute Congestive Heart Failure: Role of BNP Measurements , 2003, Heart Failure Reviews.
[78] A. Torbicki,et al. N‐terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism , 2003, European Respiratory Journal.
[79] I. Squire,et al. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate , 2003, European journal of heart failure.
[80] T. McDonagh,et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.
[81] Euan A Ashley,et al. Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction , 2003, Circulation.
[82] G. Merlini,et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. , 2003, Clinical chemistry.
[83] A. Wu,et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. , 2003, The American journal of cardiology.
[84] F. Horkay,et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. , 2003, Biochemical and biophysical research communications.
[85] I. Squire,et al. Myotrophin in human heart failure. , 2003, Journal of the American College of Cardiology.
[86] G. Fonarow,et al. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.
[87] D. vesely,et al. Natriuretic peptides and acute renal failure. , 2003, American journal of physiology. Renal physiology.
[88] I. Hisatome,et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. , 2003, Journal of cardiac failure.
[89] I. Squire,et al. Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.
[90] U. Dahlström,et al. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. , 2003, Clinical chemistry.
[91] R. Califf,et al. N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.
[92] D. Levy,et al. Heritability and Genetic Linkage of Plasma Natriuretic Peptide Levels , 2003, Circulation.
[93] S. Mudaliar,et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.
[94] C. Frampton,et al. B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.
[95] P. Palatini,et al. C-reactive protein in acute myocardial infarction: association with heart failure. , 2003, American heart journal.
[96] Richard Kamin,et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.
[97] M. Silver,et al. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. , 2003, Congestive heart failure.
[98] P. Hanrath,et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. , 2003, The American journal of cardiology.
[99] L. Fisher,et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.
[100] J. van der Linden,et al. Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the Maze procedure. , 2003, The Annals of thoracic surgery.
[101] J. Hollander,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[102] Richard T. Lee,et al. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.
[103] S. Anker,et al. Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure , 2003 .
[104] M. Emdin,et al. Influence of Gender on Circulating Cardiac Natriuretic Hormones in Patients with Heart Failure , 2003, Clinical chemistry and laboratory medicine.
[105] I. Squire,et al. Plasma Urotensin in Human Systolic Heart Failure , 2002, Circulation.
[106] J. Herlitz,et al. N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002, Circulation.
[107] C. Zanker,et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.
[108] J. Cohn,et al. Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.
[109] D. Duprez,et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.
[110] D. Levy,et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.
[111] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[112] A. Richards,et al. Plasma urotensin II in heart failure , 2002, The Lancet.
[113] A. Richards,et al. Plasma brain natriuretic peptide after long‐term treatment for heart failure in general practice , 2002, European journal of heart failure.
[114] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[115] M. Mcmurdo,et al. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. , 2002, Age and ageing.
[116] S. Douglas,et al. Congestive heart failure and expression of myocardial urotensin II , 2002, The Lancet.
[117] M. Redfield,et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.
[118] J. Alonso-Martínez,et al. C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.
[119] R. Berger,et al. B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.
[120] M. Pfeffer,et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.
[121] L. Ng,et al. Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure. , 2002, Clinical science.
[122] A. DeMaria,et al. Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.
[123] A. DeMaria,et al. Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction , 2002 .
[124] A. Maggioni,et al. Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure , 2002, Clinical chemistry and laboratory medicine.
[125] M. Vogeser,et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[126] R. Doughty,et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.
[127] M. Kinoshita,et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[128] P. Krishnaswamy,et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.
[129] M. Vogeser,et al. Clinical value of brain natriuretic peptide for candidate selection before cardiac transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[130] L. Lenert,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.
[131] H. Hense,et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.
[132] L. Ng,et al. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. , 2000, Clinical science.
[133] Y. Murakami,et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. , 2000, Journal of cardiac failure.
[134] M. Enriquez-Sarano,et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. , 2000, Journal of the American College of Cardiology.
[135] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[136] D. Murdoch,et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.
[137] F. Follath,et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. , 1999, American heart journal.
[138] G. MacGregor,et al. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. , 1998, Clinical science.
[139] C. Frampton,et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.
[140] B. Cheung. PLASMA CONCENTRATION OF BRAIN NATRIURETIC PEPTIDE IS RELATED TO DIASTOLIC FUNCTION IN HYPERTENSION , 1997, Clinical and experimental pharmacology & physiology.
[141] A. Richards,et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.
[142] S. Steinhubl,et al. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. , 2007, American heart journal.
[143] K. Swedberg,et al. Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. , 2005, The Canadian journal of cardiology.
[144] A. Maisel,et al. B-Type Natriuretic Peptide: The Level and the Drug— Partners in the Diagnosis and Management of Congestive Heart Failure , 2004 .
[145] U. Janssens,et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. , 2004, American heart journal.
[146] P. McCullough,et al. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. , 2003, Reviews in cardiovascular medicine.
[147] D. Morrow,et al. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. , 2003, Reviews in cardiovascular medicine.
[148] T. McDonagh,et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. , 2003, Journal of the American College of Cardiology.
[149] W. Uhl,et al. The influence of renal function on NT-proBNP levels in various disease groups. , 2003, Clinical laboratory.
[150] Leong L. Ng,et al. Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure , 2002 .